Craig Adam R 4
4 · CTI BIOPHARMA CORP · Filed Jan 26, 2023
Insider Transaction Report
Form 4
Craig Adam R
DirectorSee Remarks
Transactions
- Sale
common stock
2023-01-24$6.00/sh−83,200$499,200→ 29,440 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-24−83,200→ 472,171 totalExercise: $0.84Exp: 2029-05-16→ Common Stock (83,200 underlying) - Exercise/Conversion
common stock
2023-01-24$0.84/sh+2,117$1,781→ 31,557 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-24−2,117→ 470,054 totalExercise: $0.84Exp: 2029-05-16→ Common Stock (2,117 underlying) - Exercise/Conversion
common stock
2023-01-24$0.84/sh+83,200$69,980→ 112,640 total - Sale
common stock
2023-01-24$6.01/sh−2,117$12,723→ 29,440 total
Footnotes (2)
- [F1]This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- [F2]One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.